Lineage Cell Therapeutics, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $5.9M | $7.0M | $5.2M | $4.4M | $3.9M | $4.4M | $3.7M |
| Cost of Revenue | $168.0K | $358.0K | $1.1M | $837.0K | $793.0K | $434.3K | $79.4K | $27.7K |
| Gross Profit | $3.3M | $5.6M | $5.9M | $4.4M | $3.6M | $3.5M | $4.4M | $3.7M |
| Gross Margin | 95.1% | 94.0% | 84.3% | 84.0% | 82.1% | 88.9% | 98.2% | 99.3% |
| Operating Expenses | ||||||||
| Research & Development | $24.0M | $36.1M | $42.6M | $37.5M | $26.6M | $18.1M | $13.7M | $8.2M |
| SG&A Expense | $19.9M | $28.4M | $29.1M | $17.6M | $15.6M | $10.4M | $9.3M | $5.3M |
| Operating Income | $-38.9M | $-59.0M | $-65.8M | $-50.7M | $-56.0M | $-25.0M | $-18.7M | $-9.9M |
| Operating Margin | -1,125.0% | -995.6% | -935.3% | -966.5% | -1,262.7% | -638.5% | -421.4% | -265.7% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-23.3M | $18.6M | $-62.7M | $-51.2M | $-56.2M | $-25.3M | $-18.4M | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-20.0M | $33.6M | $-47.0M | $-36.4M | $-43.9M | $-21.4M | $-16.5M | $-11.2M |
| Net Margin | -577.7% | 566.8% | -667.9% | -694.4% | -989.7% | -547.2% | -372.5% | -301.6% |
| EPS (Basic) | $-0.17 | $0.35 | $-0.59 | $-0.55 | $-0.81 | $-0.44 | $-0.35 | $-0.28 |
| EPS (Diluted) | $-0.17 | $0.34 | $-0.59 | $-0.55 | $-0.81 | $-0.44 | $-0.35 | $-0.28 |
| Shares Outstanding (Basic) | 114.5M | 97.3M | 79.7M | 66.5M | 56.7M | 49.4M | 49.0M | 47.8M |
| Shares Outstanding (Diluted) | 114.5M | 99.6M | 79.7M | 66.5M | 56.7M | 49.4M | 49.0M | 47.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |